

November 10, 2022

BrightPath to Update the Pre-clinical Data of iPS-NKT at SITC 2022

Tokyo, Japan - November 10, 2022/ -- BrightPath Biotherapeutics (TSE Growth 4954), a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapeutics, today announced a presentation of the pre-clinical data on iPS-NKT program at the Society for Immunotherapy of Cancer Annual Meeting (SITC 2022, November 8-12, Boston).

The presentation is available on the websites of [BrightPath](#).

BrightPath's abstract is as follows:

Title: A novel iPSC-derived CAR-invariant natural killer T (iNKT) cell therapy platform for hematologic malignancies and solid tumors
(Abstract number: 290)

The presentation describes:

- **BrightPath produced the first-ever iPS-NKT Platform-derived prototype CAR-iPSNKT cells targeting CD19 or HER2 that demonstrated *in vitro* antitumor effects**
- **CD19 CAR- or HER2 CAR-transduced iPSCs were differentiated into CAR-iNKT cells in feeder cell-free culture conditions while maintaining CAR expression.**

iPS-NKT is novel allogeneic cell therapy platform that uses natural killer T (NKT) cells differentiated from iPSC for cancer treatment. At present, an investigator-initiated Phase 1 trial of iPS-NKT in patients with head and neck cancers is underway at Chiba University as the world's first clinical application of iPSC-derived NKT cells for cellular therapy.

iNKT cells are a rare subset of innate lymphocytes that bridge innate and adaptive immune response. The most distinct feature of iNKT cells from other immune cells is the function to prime host endogenous T cells, which is expected to provide durability of response in the clinical practice.

One of the challenge is a clinical-scale manufacturing from such a rare subset and Use of iPSC derived from iNKT cells is an ideal strategy to realize clinical scale production of functional iNKT cells from such a rare population.

To demonstrate that CAR-transduced iPSC-derived iNKT cells provide a novel platform for effective cancer immunotherapy, the killing activities of CD19 CAR- or HER2 CAR-transduced iPSC-derived iNKT cells were investigated in this first set of studies.

About BrightPath:

BrightPath is a clinical stage biopharmaceutical company focused on the development of novel cancer immuno-therapies to transform cancer treatment for refractory or progressive cancers that cannot be treated with conventional standard therapies. BrightPath is actively involved in

developing cell therapies currently in clinical trials, immunomodulatory antibodies and new drug targeted at cancer specific neoantigens.

For more information, visit www.brightpathbio.com/english/index.html.

Forward-Looking Statements:

This news release contains forward-looking statements that are based on the current expectations and beliefs of BrightPath. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. BrightPath cautions that these forward-looking statements do not guarantee our future financial results but involve risks and uncertainties that could cause actual results to differ materially from those discussed in the forward-looking statements. These forward-looking statements speak only as of the date of this press release and BrightPath assumes no duty to update forward-looking statements, except as may be required by law.

Investor and Media Contact:

+81-3-5840-7697

irpr@brightpathbio.com

www.brightpathbio.com/english/index.html